A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

Inclusion Criteria: * 18≤ age ≤60, 18 kg/m2 ≤BMI ≤28 kg/m2, male or female; * Diagnosed with 2019-nCoV infection and classified clinically as mild or general; * Agreed not to participate in other clinical studies before completing this study; * With the subject's consent and signed informed consent form by the subject or his/her legal representative. Exclusion Criteria: * Diagnosed with 2019-nCoV infection and classified clinically as severe or critical severe; severe pneumonia or acute respiratory distress syndrome, sepsis and septic shock; * The disease would deteriorate significantly within 48 hours judged by the investigators; * Immunodeficiency or immune related diseases not suitable for participation judged by the investigators (such as autoimmune diseases, IgG4 related diseases, allergic alveolitis, vasculitis, etc); * Lymphocyte count \<0.5×109/L; * Neutropenia history (neutrophil absolute count was less than 2×109/L in adults), except for infection; * D- dimer \>2000 µg/L; * Severe history of lung diseases, such as chronic obstructive pulmonary disease, lung cancer, tuberculosis, etc., history of heart disease: unstable angina pectoris, myocardial infarction, cardiac surgery, cardiac function≥ grade 3 (NYHA classification), serious history of liver disease (such as Child Pugh score ≥grade C), serious renal disease history, such as renal insufficiency (GFR ≤ 15ml/min/1.73m2), etc; * The subjects used the following drugs within 2 weeks (including 2 weeks) before screening: 1. Calcineurin inhibitors (such as cyclosporin and tacrolimus); 2. Proliferation inhibitors (such as everolimus, sirolimus, etc); 3. anti-metabolic agents (such as mycophenolate mofetil, mycophenolic acid, purine sulfate, etc); * Pregnant or lactating women.